To maintain glucose homeostasis, patients with type 1 diabetes mellitus (T1D) require continuous glucose monitoring and exogenous insulin treatment due to the autoimmune destruction of their insulin-producing β-cells. This evidence concerns the gene INS and type 1 diabetes mellitus.